Clarus Bets Big: Eyes Big Investments, New Fund
This article was originally published in Start Up
Executive Summary
Clarus Ventures, a year-and-a-half removed from raising its debut fund, likely will return for seconds later this year, and the firm is betting its new strategy for investing in medical device companies promises to produce returns that its limited partners will enjoy.
You may also be interested in...
Sientra Looks Good: $80 million Series B Could Help Build Platform
A deep-pocketed syndicate--Orbimed Advisors, Clarus Ventures, TIAA-CREF and Goldman Sachs--supply $80 million to start Sientra, a seller of silicone breast implants and other aesthetics devices.
Biomet Deal Opens Door for PE Buyers
A $10.9 billion bid by a consortium of private equity investors to buy Biomet raises questions about whether this is the first of many such deals or an outlier.
Choose One, Not Both: Why Balanced Biopharma Funds Stumble
By the end of this year, three major US venture firms---JP Morgan Partners, the American affiliate of Apax, and MPM Capital--will be transformed. Their partners are leaving; their strategies are changing. And their stories are all marked by their common failure to combine early-stage biopharmaceutical venture capital with later-stay growth capital and buyouts into so-called "balanced funds."